Here are the top 5 biosimilar articles for the week of February 8, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of February 8, 2021.
Number 5: An 80-week observational studysuggests a non-medical switch from infliximab to SB2 is “a feasible option” for patients with inflammatory bowel diseases.
Number 4: A patient in a hospital outpatient setting was 42% less likely to receive a filgrastim biosimilar than a patient in an office setting, but 73% more likely to receive an infliximab biosimilar, according to a large, cross-sectional study.
Number 3: Biosimilar competition took a big chunk of revenue from Roche's aging blockbusters in 2020, and the company is banking on its newer medicines to drive fresh revenue growth.
Number 2: Celltrion Healthcare has received Canadian authorization to market a subcutaneous formulation of the infliximab biosimilar Remsima (Remsima SC; CT-P13).
Number 1: During its 2020 earnings call, Amgen described how a double-edged biosimilars sword has worked for and against the company's profit margin.
To read all of these articles and more, visit centerforbiosimilars.com.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.